Investment
Features
FeesSafety
Academy
More
Pluang+

Over 1,500 pounds of imported pork recalled in US over listeria risk

Market News
08 Sep 2026
Fox Business
View Source
Bearish
Over 1,500 pounds of imported pork recalled in US over listeria risk

More than 1,500 pounds of imported ready-to-eat pork products, specifically dry-cured pork jowl (guanciale), have been recalled in the US due to potential contamination with Listeria monocytogenes. The recall, classified as Class I by the USDA, involves products from Prime Line Distributors in Florida and Ferrarini USA in New Jersey, with items produced in Italy. The contamination was found during routine testing, and the products were distributed across several states including Florida, California, and New York. Listeria infection can cause serious health issues, especially for older adults, pregnant women, and those with weakened immune systems. Consumers and retailers are urged to discard or return the products and seek medical advice if symptoms appear after consumption. No illnesses have been reported so far.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
1 hour ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
2 hours ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
3 hours ago
Near Protocol (NEAR) jumps nearly 6% amid $280K short liquidations on major exchanges

Near Protocol (NEAR) jumps nearly 6% amid $280K short liquidations on major exchanges

Near Protocol (NEAR) surged to $5.28, rising 5.94% within four hours on October 6, driven by $280,000 worth of short position liquidations across Binance, Bybit, and OKX. The price climbed from $4.98 during this period and showed a 7.14% gain over th...

Market News
Bullish
4 hours ago
Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

A class action lawsuit has been filed against Alphabet Inc. for allegedly making false and misleading statements about the performance and launch delays of its Gemini 3.5 Pro product between May 19 and July 16, 2026. The lawsuit claims these misstate...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App